Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Collection of Peripheral Blood and Bone Marrow From Healthy Donors for Use in In Vitro Research

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2014 by National Institutes of Health Clinical Center (CC)
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Institute of Allergy and Infectious Diseases (NIAID) ) Identifier:
First received: September 1, 2004
Last updated: November 11, 2014
Last verified: January 2014

Increased numbers of white blood cells called eosinophils can cause disease. To investigate this disease, researchers need normal blood and bone marrow samples to compare to samples from patients with this problem. This study will collect blood and bone marrow samples from normal volunteers who meet standard blood donor criteria. Some of the samples will be used for genetic testing or future research.

This study will last for about 3 years and will include a maximum of 50 paid volunteers ages 18 to 65.

After a medical screening, volunteers will donate a blood sample and a bone marrow sample, taken from the hip bone, followed by a biopsy that will obtain a small sample of bone and bone marrow. The procedure lasts less than 1 hour. Volunteers may donate repeatedly within the limits set by the study.


Study Type: Observational
Official Title: Collection of Peripheral Blood, Urine, Sputum, and Bone Marrow From Healthy Donors for Use in In Vitro Research

Further study details as provided by National Institutes of Health Clinical Center (CC):

Estimated Enrollment: 150
Study Start Date: August 2004
Detailed Description:

This protocol is designed to provide blood, urine, sputum, and bone marrow aspirate samples from paid, volunteer donors for use in in vitro studies of eosinophilia. Donors meeting standard blood, urine, and sputum donor eligibility criteria will be recruited to donate blood, urine, sputum, and/or bone marrow using conventional techniques. The investigational nature of the studies in which their samples will be used, as well as the risks and benefits of the donation process will be explained to all donors, and a signed informed consent document will be obtained. Donors will be compensated according to an established schedule based on the duration and discomfort of the donation. Samples provided through this protocol will be used solely for in vitro research. Blood, urine, sputum and bone marrow samples will be assigned a unique product number, and the study investigators listed on this protocol will serve as the custodians of the code that links the product with a donor's identity. The nature of the in vitro studies in which the specimens collected in this study will be used is not the subject of this protocol and will be described in general terms only, since it involves several IRB approved LPD protocols. This protocol is designed to assure adequate and complete informed consent, counseling and protection of the study subjects according to IRB, OHSR, OPRR and other applicable Federal regulatory standards.


Ages Eligible for Study:   18 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
  • Eligibility criteria for volunteer whole blood donation are based on the Standards of the AABB(2) and the Code of Federal Regualtions 21 CFR 640(3). Specific criteria follow:


  • Ability to sign informed consent.
  • Healthy, male or female, and 18-85 years of age.

Eligibility criteria for volunteer bone marrow donation are more stringent than those for other specimen donations to minimize risk of procedure complications and maximize utility of specimens for study:

Bone Marrow Donation

  • Ability to sign informed consent.
  • Healthy, male or female, and 18 65 years of age


  • Pregnancy
  • Weight less than 110 pounds
  • History of heart, lung kidney disease, chronic anemia or bleeding disorders

Bone Marrow Donation

  • A known bleeding disorder, low platelets (less than 100k) or taking medications that interfere with blood clotting, such as aspirin, non-steroidal anti-inflammatory agents or warfarin
  • Anemia (hemoglobin less than 12.3 mg/dL).
  • Evidence of an immune deficiency, such as HIV infection or cancer.
  • Pregnancy.
  • Taking a medication that affects eosinophils, including steroids, beta-blockers and agents that affect the immune response.
  • Allergic to xylocaine.
  • Have taken an investigational drug in the last 6 months.
  • Any other medical condition that the investigator feels puts the participant at too high a risk for participation.

Warfarin and/or heparin treatment will not be stopped so that a subject can participate in this protocol. If warfarin or heparin was recently discontinued, a subject can be enrolled, but no bone marrow procedures will be performed until the PT is less than 15.5 seconds and the PTT is within normal range. For other agents that interfere with blood clotting without prolonging the PT, a 7 day washout period will be required before bone marrow sampling.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00090662

Contact: Tamika S Magee, R.N. (301) 443-5458
Contact: Amy D Klion, M.D. (301) 435-8903

United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike Recruiting
Bethesda, Maryland, United States, 20892
Contact: For more information at the NIH Clinical Center contact Patient Recruitment and Public Liaison Office (PRPL)    800-411-1222 ext TTY8664111010   
Sponsors and Collaborators
Principal Investigator: Amy D Klion, M.D. National Institute of Allergy and Infectious Diseases (NIAID)
  More Information

Additional Information:
No publications provided

Responsible Party: National Institutes of Health Clinical Center (CC) ( National Institute of Allergy and Infectious Diseases (NIAID) ) Identifier: NCT00090662     History of Changes
Other Study ID Numbers: 040266, 04-I-0266
Study First Received: September 1, 2004
Last Updated: November 11, 2014
Health Authority: United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):
Normal Volunteer
Bone Marrow
Volunteer Donors
Healthy Volunteer
HV processed this record on November 20, 2014